Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Nov 09, 2023 10:30am
222 Views
Post# 35725981

Marsolais and LaFond not buyers

Marsolais and LaFond not buyersI think these are the only two senior managers that I would have expected to buy shares like other insiders that did not do so. 

I wonder if special accomodations have been made for these two who were blocked out for a very long time from exercising their long held options at levels that would have been profitable for them and this is why they did not participate in the recent buying? Their options are no longer in the money and will likely expire worthless if they have not done so already.

If THTX has done something to make them somewhat whole or at least give them a chance to get whole sometime in the future, that would be nice as they were trapped for the better part of a year without being able to exercise those options. I only wish the same could be done for legacy shareholders too!

If they have done something for those two I would like to know about it as otherwise the lack of joining in the buying by Marsolais, in particular, makes one wonder why.
<< Previous
Bullboard Posts
Next >>